This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The control group comprised 44 children who were hospitalised between December 1994 and February 1995. The mean age was 3.2 years, and 47.7% were boys. Of these, 23 children were given one agent, 19 received two agents, and 2 were treated with three agents. No other baseline characteristics were given, although the groups were compared statistically in terms of their body temperature, and creatinine and urea levels.
Study design
The study was a non-randomised controlled trial with historical controls, carried out in a single centre (Antrim Area Hospital). The intervention data were gathered between December 1995 and February 1996, whilst the control data were gathered between December 1994 and February 1995. SAT-treated children were followed for 4 to 6 weeks after their discharge from hospital. The length of follow-up was not given for the control group. The parents of the children in the SAT group were given a questionnaire on their child's clinical progress after discharge.
Analysis of effectiveness
All the children included in the study were accounted for in the analysis. This implied that the analysis was performed on an intention to treat basis.
The two primary health outcomes were treatment success and treatment failure. Treatment success was defined as a major improvement or complete resolution of all signs and symptoms. Treatment failure was defined as the persistence or progression of signs and symptoms, the presence of adverse effects, active infection or death. The outcome measures were evaluated retrospectively (from hospital records) for the children in the control group, and prospectively (from the parents' questionnaire) for the children in the SAT group. The length of hospital stay and the number of days of intravenous and oral antimicrobial therapies were also considered, but these were only used as resources in the cost analysis.
There were no statistically-significant differences between the groups with respect to age, gender, and clinical characteristics, (p=0.119 or p>0.119). However, the two groups did differ in the type of antibiotics used, although this difference was not tested statistically.
Effectiveness results
Both the SAT and control therapies were stated to be effective in terms of treatment success. However, no differentiation was made between "major improvement" and "complete resolution". In addition, the result for nonrecurrence was only given for the SAT group.
The mean (geometric) duration of hospital stay was significantly longer in the control group (8.3 days) than in the SAT group (4 days), (p<0.001).
The mean (geometric) duration of intravenous antimicrobial therapy was greater in the control group (5.6 days) than in the SAT group (1.7 days), (p<0.001). Similarly, the mean duration of antimicrobial therapy was greater in the control group (7.9 days) than in the SAT group (4 days), (p<0.001).
The mean (geometric) duration of oral antimicrobial therapy was not statistically different between the control (2 days) and SAT (2.2 days) groups.
Clinical conclusions
Both of the interventions were equally effective with respect to the main outcome measure (treatment success). The secondary outcomes (duration of stay and therapy) were significantly reduced in the SAT group.
Measure of benefits used in the economic analysis
The main health outcome of treatment success was used in the effectiveness analysis. Since this was claimed to be equal in the two groups, the authors stated that a cost-minimisation analysis was performed.
Validity of estimate of measure of effectiveness
The internal validity of the study may have been adversely affected by the lack of randomisation when allocating the patients to the treatment groups. Although the comparability of groups with respect to demographics and clinical conditions was shown statistically, the role of confounding variables and selection bias cannot be ruled out. Further, secondary health outcomes were reported, but these were not included in the analysis and were used only as resource use data.
Also, some confounding was not accounted for:
The length of follow-up was not given for the control group and was variable for the SAT group was variable, although this variation was not reported.
It was unclear what the final outcome was. It was deduced that all the children in the SAT group achieved complete resolution (no recurrence was reported), but the resolution statistics were not given for the control group.
The nature of the therapy was also varied in terms of the type of antibiotic used, which was not accounted for.
Finally, the claim of equal effectiveness was based only on resolution of signs and symptoms, and not time to resolution. There was evidence of differences in the length of hospital stay and the duration of antibiotic use, which contradicts the claim of equal effectiveness.
It would have been interesting if the authors had produced a summary benefit measure.
Validity of estimate of measure of benefit
Not applicable.
Validity of estimate of costs
The unit costs and quantities were, generally, not reported separately, and sensitivity analyses were not performed. Consequently, the pattern of resource use by treatment groups was unknown and the generalisability of the study was limited. In addition, the costs included were fairly specific to the study setting. It would have been useful to have adopted a societal perspective and included the indirect costs, which are mainly borne by the families of the hospitalised children. However, the inclusion of such costs might have partially increased the advantage of SAT over long-term intravenous therapy, since SAT is associated with shorter hospital stay.
Other issues
The findings of the analysis were similar to those reported in other studies. However, the generalisability of the study to other settings appears to have been limited. The effectiveness results were not reported fully. Also, the conclusions relating to the equal effectiveness of both strategies were questionable.
Implications of the study
SAT was associated with consistent health care cost-savings and should be recommended for paediatric patients hospitalised with severe respiratory tract infections. However, as has been clearly argued, there were serious methodological flaws on both the effectiveness and cost sides of the study.
